Anchiano Therapeutics inodiftagene vixteplasmid bladder cancer

Anchiano starts Codex study for bladder cancer drug

Anchiano Therapeutics has commenced a Phase II Codex trial examining the efficacy and safety of inodiftagene vixteplasmid (BC-819) for the…